• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接受经皮冠状动脉介入治疗的口服抗凝药治疗老年患者的临床特征、治疗策略及结局:PERSEO注册研究分析

Clinical characteristics, therapeutic strategies, and outcomes in elderly patients on oral anticoagulant therapy undergoing percutaneous coronary interventions: analysis of the PERSEO Registry.

作者信息

Minardi Simona, De Rosa Salvatore, Salvi Nicolò, Andò Giuseppe, Talanas Giuseppe, D'angelo Claudio, Moretti Carolina, Mazza Tiziano Maria, Cortese Bernardo, Musumeci Giuseppe, Rubboli Andrea, Sciahbasi Alessandro

机构信息

Division of Cardiology, Sant'Eugenio Hospital, Rome, Italy.

Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy.

出版信息

J Geriatr Cardiol. 2025 Aug 28;22(8):701-708. doi: 10.26599/1671-5411.2025.08.002.

DOI:10.26599/1671-5411.2025.08.002
PMID:40919345
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12411762/
Abstract

BACKGROUND

Antithrombotic strategies after percutaneous coronary interventions (PCI) in elderly patients on oral anticoagulant therapy (OAT) are debated due to the balance between ischemic and bleeding risks. Recent guidelines recommend early transitioning from triple antithrombotic therapy to dual antithrombotic therapy, but there are limited data on elderly patients.

METHODS

We performed a age-specific analysis of the PERSEO Registry population aimed to compare clinical features, therapeutic strategies, and outcomes of individuals aged ≥ 80 years and < 80 years who were on OAT and underwent PCI with stent. The primary endpoint was net adverse clinical events at 1-year follow-up. Secondary endpoints included major adverse cardiac and cerebral events (MACCE), major bleeding [Bleeding Academic Research Consortium (BARC) type 3-5], and clinically relevant bleeding (BARC type 2-5).

RESULTS

Among the 1234 patients enrolled, 31% of patients were aged ≥ 80 years (84 ± 3 years, 76% males). Compared to younger patients, elderly patients had higher rates of comorbidities such as hypertension, anaemia or chronic kidney disease, and atrial fibrillation was the leading indication for OAT. Elderly patients were more often discharged on dual antithrombotic therapy (23%) compared to younger patients (13%) ( < 0.0001). They experienced higher net adverse clinical events (38% 21%, < 0.001), MACCE (24% 12%, < 0.001), as well as higher bleeding rates. Specifically, rates of major bleeding (9% 6%, = 0.026), and clinically relevant bleeding (21% 12%, < 0.001) were significantly higher in elderly patients.

CONCLUSIONS

Elderly patients on OAT undergoing PCI are a particular frail population with higher risk of MACCE and bleeding compared to younger patients despite a less aggressive antithrombotic therapy.

摘要

背景

口服抗凝治疗(OAT)的老年患者经皮冠状动脉介入治疗(PCI)后的抗栓策略因缺血风险和出血风险之间的平衡而存在争议。近期指南推荐早期从三联抗栓治疗过渡到双联抗栓治疗,但老年患者的数据有限。

方法

我们对PERSEO注册研究人群进行了年龄特异性分析,旨在比较接受OAT且接受支架植入PCI的≥80岁和<80岁个体的临床特征、治疗策略及结局。主要终点为1年随访时的净不良临床事件。次要终点包括主要不良心脑血管事件(MACCE)、大出血[出血学术研究联盟(BARC)3 - 5型]和临床相关出血(BARC 2 - 5型)。

结果

在纳入的1234例患者中,31%的患者年龄≥80岁(84±3岁,76%为男性)。与年轻患者相比,老年患者合并症发生率更高,如高血压、贫血或慢性肾脏病,且房颤是OAT的主要适应证。与年轻患者(13%)相比,老年患者更常接受双联抗栓治疗出院(23%)(P<0.0001)。他们经历了更高的净不良临床事件(38%对21%,P<0.001)、MACCE(24%对12%,P<0.001),以及更高的出血率。具体而言,老年患者的大出血发生率(9%对6%,P = 0.026)和临床相关出血发生率(21%对12%,P<0.001)显著更高。

结论

接受OAT且接受PCI的老年患者是一个特别脆弱的人群,尽管抗栓治疗不那么积极,但与年轻患者相比,发生MACCE和出血的风险更高。

相似文献

1
Clinical characteristics, therapeutic strategies, and outcomes in elderly patients on oral anticoagulant therapy undergoing percutaneous coronary interventions: analysis of the PERSEO Registry.接受经皮冠状动脉介入治疗的口服抗凝药治疗老年患者的临床特征、治疗策略及结局:PERSEO注册研究分析
J Geriatr Cardiol. 2025 Aug 28;22(8):701-708. doi: 10.26599/1671-5411.2025.08.002.
2
Indobufen versus aspirin after percutaneous coronary intervention in elderly patients with acute coronary syndrome.吲哚布芬与阿司匹林用于老年急性冠状动脉综合征患者经皮冠状动脉介入治疗后的比较
BMC Cardiovasc Disord. 2025 Jul 7;25(1):495. doi: 10.1186/s12872-025-04843-0.
3
Pharmacodynamic effects of early aspirin withdrawal after percutaneous coronary intervention in patients with atrial fibrillation treated with ticagrelor or prasugrel.替格瑞洛或普拉格雷治疗的房颤患者经皮冠状动脉介入治疗后早期停用阿司匹林的药效学效应
Platelets. 2025 Dec;36(1):2507037. doi: 10.1080/09537104.2025.2507037. Epub 2025 May 23.
4
Management of Patients Treated With Oral Anticoagulant Therapy Undergoing Percutaneous Coronary Intervention With Stent Implantation: The PERSEO Registry.经皮冠状动脉介入治疗(PCI)中接受口服抗凝治疗的患者管理:PERSEO 注册研究。
J Cardiovasc Pharmacol. 2024 Oct 1;84(4):457-467. doi: 10.1097/FJC.0000000000001607.
5
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
6
Long-term outcome of tailored antithrombotic therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a 5-year retrospective cohort study.经皮冠状动脉介入治疗患者基于血小板功能检测的个体化抗栓治疗的长期结局:一项5年回顾性队列研究
Heart Vessels. 2025 Aug 21. doi: 10.1007/s00380-025-02584-w.
7
Peri-Procedural Management of Oral Anticoagulant Therapy in Patients Undergoing Percutaneous Coronary Intervention: Insights from the PERSEO Multicenter Registry.接受经皮冠状动脉介入治疗患者的口服抗凝治疗围手术期管理:来自PERSEO多中心注册研究的见解
Catheter Cardiovasc Interv. 2025 Aug;106(2):1177-1186. doi: 10.1002/ccd.31657. Epub 2025 Jun 4.
8
Deescalation From Ticagrelor to Clopidogrel for Myocardial Infarction With Chronic Kidney Disease: A Secondary Analysis of a Randomized Clinical Trial.从替格瑞洛降阶梯至氯吡格雷用于慢性肾脏病合并心肌梗死:一项随机临床试验的二次分析
JAMA Netw Open. 2025 May 1;8(5):e2511297. doi: 10.1001/jamanetworkopen.2025.11297.
9
Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia.抗血栓治疗预防神经影像学检查发现的小血管疾病但无痴呆的患者认知能力下降。
Cochrane Database Syst Rev. 2022 Jul 14;7(7):CD012269. doi: 10.1002/14651858.CD012269.pub2.
10
Antithrombotic treatment after stroke due to intracerebral haemorrhage.脑出血所致脑卒中后的抗血栓治疗。
Cochrane Database Syst Rev. 2023 Jan 26;1(1):CD012144. doi: 10.1002/14651858.CD012144.pub3.

本文引用的文献

1
Managing elderly patients with atrial fibrillation and multimorbidity: call for a systematic approach.管理患有心房颤动和多种合并症的老年患者:呼吁采取系统方法。
Expert Rev Cardiovasc Ther. 2024 Oct;22(10):523-536. doi: 10.1080/14779072.2024.2416666. Epub 2024 Oct 24.
2
Recent Advances in the Management of Non-rheumatic Atrial Fibrillation: A Comprehensive Review.非风湿性心房颤动管理的最新进展:全面综述
Cureus. 2024 Jul 31;16(7):e65835. doi: 10.7759/cureus.65835. eCollection 2024 Jul.
3
2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).2024年欧洲心脏病学会(ESC)心房颤动管理指南,与欧洲心胸外科学会(EACTS)联合制定。
Eur Heart J. 2024 Sep 29;45(36):3314-3414. doi: 10.1093/eurheartj/ehae176.
4
Management of Patients Treated With Oral Anticoagulant Therapy Undergoing Percutaneous Coronary Intervention With Stent Implantation: The PERSEO Registry.经皮冠状动脉介入治疗(PCI)中接受口服抗凝治疗的患者管理:PERSEO 注册研究。
J Cardiovasc Pharmacol. 2024 Oct 1;84(4):457-467. doi: 10.1097/FJC.0000000000001607.
5
Temporary omission of oral anticoagulation in atrial fibrillation patients undergoing percutaneous coronary intervention: rationale and design of the WOEST-3 randomised trial.经皮冠状动脉介入治疗的心房颤动患者中暂时停用口服抗凝剂:WOEST-3 随机试验的原理和设计。
EuroIntervention. 2024 Jul 15;20(14):e898-e904. doi: 10.4244/EIJ-D-24-00100.
6
Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.行经皮冠状动脉介入治疗的心房颤动患者的抗栓治疗优化
J Clin Med. 2023 Dec 23;13(1):98. doi: 10.3390/jcm13010098.
7
Bleeding risk factors and real-world antithrombotic therapies in elderly patients with atrial fibrillation undergoing percutaneous coronary intervention: a retrospective study.行经皮冠状动脉介入治疗的老年房颤患者的出血危险因素及现实世界中的抗栓治疗:一项回顾性研究
J Pharm Health Care Sci. 2023 Dec 12;9(1):41. doi: 10.1186/s40780-023-00308-8.
8
Design of the PERSEO Registry on the management of patients treated with oral anticoagulants and coronary stent.PERSEO 注册研究:口服抗凝药物和冠状动脉支架治疗患者的管理
J Cardiovasc Med (Hagerstown). 2022 Nov 1;23(11):738-743. doi: 10.2459/JCM.0000000000001372. Epub 2022 Sep 7.
9
ANMCO position paper on antithrombotic treatment of patients with atrial fibrillation undergoing intracoronary stenting and/or acute coronary syndromes.意大利心脏病学国家协会关于接受冠状动脉内支架置入和/或急性冠状动脉综合征的房颤患者抗栓治疗的立场文件。
Eur Heart J Suppl. 2022 May 18;24(Suppl C):C254-C271. doi: 10.1093/eurheartj/suac020. eCollection 2022 May.
10
Antithrombotic strategy variability in atrial fibrillation and obstructive coronary disease revascularised with percutaneous coronary intervention: primary results from the AVIATOR 2 international registry.抗栓策略在经皮冠状动脉介入治疗的心房颤动和阻塞性冠状动脉疾病中的变异性:来自 AVIATOR 2 国际注册研究的主要结果。
EuroIntervention. 2022 Oct 7;18(8):e656-e665. doi: 10.4244/EIJ-D-21-01044.